Skip to content

A Complete Guide: Can Elderly Get the RSV Vaccine?

4 min read

Each year in the U.S., RSV leads to as many as 160,000 hospitalizations and 10,000 deaths among adults 65 and older. So, can elderly get the RSV vaccine to prevent this? The answer is a definitive yes, based on a conversation with a healthcare provider.

Quick Summary

Adults aged 60 and older are recommended to get the RSV vaccine to protect against severe respiratory illness, following a discussion with their healthcare provider.

Key Points

  • CDC Recommendation: Adults aged 60 and over can get a single dose of the RSV vaccine based on shared clinical decision-making with their doctor.

  • High-Risk Focus: Vaccination is especially important for seniors with chronic heart or lung disease, weakened immune systems, or those in long-term care facilities.

  • Two Approved Vaccines: Both Arexvy (GSK) and Abrysvo (Pfizer) are safe, FDA-approved options that are highly effective at preventing severe RSV illness.

  • Proven Efficacy: Clinical trials show the vaccines reduce the risk of serious lower respiratory tract disease from RSV by over 80%.

  • Mild Side Effects: The most common side effects are temporary and mild, such as injection site soreness, fatigue, and headache.

  • Medicare Coverage: For most seniors, the RSV vaccine is covered by Medicare Part D with no out-of-pocket cost.

In This Article

Understanding RSV and Its Impact on Older Adults

Respiratory Syncytial Virus (RSV) is a common respiratory virus that typically causes mild, cold-like symptoms. While most people recover in a week or two, RSV can be serious, especially for infants and older adults. For seniors, a simple cold can quickly escalate into a severe infection like bronchiolitis (inflammation of the small airways in the lung) or pneumonia.

Why is the risk so much higher for the elderly? As people age, their immune systems naturally weaken, a process called immunosenescence. This makes it harder for the body to fight off infections. Furthermore, many older adults have underlying health conditions that can be exacerbated by an RSV infection, including:

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Asthma
  • Congestive Heart Failure
  • Coronary Artery Disease
  • Weakened Immune Systems (due to disease or medication)

For these individuals, an RSV infection can lead to hospitalization, long-term disability, and even death, making preventive measures crucial.

The CDC's Official Recommendation: Shared Clinical Decision-Making

In 2023, the U.S. Food and Drug Administration (FDA) approved the first-ever RSV vaccines for older adults. Following this, the Centers for Disease Control and Prevention (CDC) issued a key recommendation.

The CDC recommends that adults ages 60 and older may receive a single dose of an RSV vaccine using shared clinical decision-making. This means there isn't a blanket recommendation for every single person over 60. Instead, seniors should have a conversation with their doctor, pharmacist, or other healthcare provider.

This discussion should cover:

  1. Personal Health Risks: Assessing if chronic conditions like heart or lung disease put the individual at high risk for severe RSV.
  2. Lifestyle Factors: Considering factors like living in a nursing home or long-term care facility where viruses can spread easily.
  3. Patient Preference: Understanding the patient's concerns and desires regarding vaccination.
  4. Vaccine Benefits and Risks: Weighing the high efficacy of the vaccine against its potential, typically mild, side effects.

The goal is to make an informed, personal decision rather than a one-size-fits-all mandate. For most healthy adults over 60, especially those with underlying conditions, the benefits of vaccination will likely outweigh the risks.

Comparing the RSV Vaccines: Arexvy vs. Abrysvo

Two primary RSV vaccines are available for older adults: Arexvy (made by GSK) and Abrysvo (made by Pfizer). Both have been proven safe and effective. While they work similarly, there are minor differences. A healthcare provider can help decide if one is preferable, but for most patients, either is an excellent choice.

Here is a comparison of the two vaccines:

Feature GSK Arexvy Pfizer Abrysvo
FDA Approval May 2023 May 2023
Mechanism Recombinant subunit vaccine (prefusion F protein) Recombinant subunit vaccine (prefusion F protein)
Target Group Adults 60 years and older Adults 60 years and older; pregnant individuals
Efficacy ~83% effective against lower respiratory tract disease (LRTD) ~89% effective against LRTD with 3+ symptoms
Administration Single intramuscular injection Single intramuscular injection
Common Side Effects Injection site pain, fatigue, muscle ache, headache Injection site pain, fatigue, headache, muscle pain

Both vaccines are highly effective at preventing serious outcomes. The choice between them often comes down to availability at a specific pharmacy or clinic. For more information, you can review the guidance provided by the CDC on RSV Vaccination for Older Adults.

Benefits and Potential Side Effects of the RSV Vaccine

The primary benefit of getting the RSV vaccine is the significant reduction in risk for severe illness. Clinical trials have shown that the vaccines are highly effective at preventing RSV-associated lower respiratory tract disease, which is the type of illness that often leads to hospitalization.

Key Benefits:

  • Reduced Hospitalizations: Lowers the chance of needing hospital care due to RSV.
  • Prevents Severe Complications: Protects against pneumonia and exacerbations of chronic conditions.
  • Peace of Mind: Provides confidence during RSV season, which typically runs from fall to spring.

Like any vaccine, the RSV vaccine can have side effects. These are generally mild and temporary, resolving on their own within a day or two.

Common Side Effects:

  • Pain, redness, or swelling at the injection site
  • Fatigue
  • Headache
  • Muscle or joint pain

Serious side effects are very rare, but have been noted in a small number of cases during studies, including atrial fibrillation and certain inflammatory neurological events. This is a primary reason the CDC recommends a discussion with a doctor who can weigh these very small risks against the much larger, more common risk of severe RSV disease in older adults.

Accessing the Vaccine: Cost and Coverage

For most seniors in the United States, the RSV vaccine should be affordable and accessible.

  1. Consult Your Doctor: Start by discussing if the RSV vaccine is right for you during your next appointment.
  2. Check with Your Pharmacy: Major pharmacies like CVS, Walgreens, and Rite Aid offer the RSV vaccine. It's often possible to get it at the same time as a flu or COVID-19 shot.
  3. Insurance Coverage: The RSV vaccine is covered under Medicare Part D. For those with a Part D plan, the vaccine should be available at no out-of-pocket cost. Private insurance plans also generally cover the vaccine, but it's always wise to confirm coverage beforehand.

Conclusion: A Proactive Step for Healthy Aging

The development of RSV vaccines marks a major milestone in public health, particularly for the senior community. It provides a powerful tool to prevent a common but potentially dangerous illness. If you are 60 or older, the answer to 'can elderly get the RSV vaccine?' is yes. The next step is to schedule a conversation with your healthcare provider to review your personal health profile and decide if this important preventive measure is the right choice for you this season.

Frequently Asked Questions

The CDC recommends that adults aged 60 and older may receive an RSV vaccine after a discussion with their healthcare provider. It is particularly encouraged for those with chronic health conditions.

Currently, the RSV vaccine is recommended as a single dose. Studies are ongoing to determine if or when a booster shot might be needed in subsequent years, but as of now, it is not an annual requirement.

Yes, according to the CDC, you can get the RSV vaccine at the same time as other vaccines. Your healthcare provider can administer the shots in different arms to minimize discomfort.

The most common side effects are mild and temporary, including pain or swelling at the injection site, fatigue, muscle aches, and headache. They typically resolve within 1-2 days.

For individuals with Medicare Part D, the RSV vaccine is generally covered with no out-of-pocket cost. Most private insurance plans also cover the vaccine, but it's best to confirm with your provider.

Both Arexvy and Abrysvo have shown high efficacy and similar safety profiles in clinical trials. There is no official recommendation of one over the other for most people. The choice often depends on availability at your pharmacy or clinic.

This approach encourages a personalized health decision. It allows you and your doctor to weigh your individual risk of severe RSV against the vaccine's benefits and very rare risks, ensuring it's the right choice for your specific health situation.

References

  1. 1
  2. 2
  3. 3

Medical Disclaimer

This content is for informational purposes only and should not replace professional medical advice. Always consult a qualified healthcare provider regarding personal health decisions.